Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy (2015)
- Autores:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1136/heartjnl-2014-305864
- Assuntos: FÁRMACOS (SISTEMA CARDIOVASCULAR); DOENÇAS CARDIOVASCULARES (TERAPIA); CUSTOS DOS CUIDADOS DE SAÚDE; CUSTOS DE MEDICAMENTOS
- Idioma: Inglês
- Imprenta:
- Fonte:
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: cc-by-nc
-
ABNT
JANZON, M. et al. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart, v. 101, n. 2, p. 119-125, 2015Tradução . . Disponível em: https://doi.org/10.1136/heartjnl-2014-305864. Acesso em: 16 abr. 2024. -
APA
Janzon, M., James, S., Cannon, C. P., Storey, R. F., Mellström, C., Nicolau, J. C., et al. (2015). Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart, 101( 2), 119-125. doi:10.1136/heartjnl-2014-305864 -
NLM
Janzon M, James S, Cannon CP, Storey RF, Mellström C, Nicolau JC, Wallentin L, Henriksson M. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy [Internet]. Heart. 2015 ; 101( 2): 119-125.[citado 2024 abr. 16 ] Available from: https://doi.org/10.1136/heartjnl-2014-305864 -
Vancouver
Janzon M, James S, Cannon CP, Storey RF, Mellström C, Nicolau JC, Wallentin L, Henriksson M. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy [Internet]. Heart. 2015 ; 101( 2): 119-125.[citado 2024 abr. 16 ] Available from: https://doi.org/10.1136/heartjnl-2014-305864 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
Informações sobre o DOI: 10.1136/heartjnl-2014-305864 (Fonte: oaDOI API)
Como citar
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
